News
Viking Therapeutics stock sinks after mixed results from its obesity pill trial, raising doubts over safety, tolerability and ...
Terence Stamp, best known for his role playing the villain General Zod in the blockbuster films Superman and Superman II, has ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.
7h
Pharmaceutical Technology on MSNNovo’s facility issues delay FDA decisions on Regeneron’s Eylea HD
Before Novo arrived as its owner, issues at the Bloomington facility caused a two-month delay for Eylea HD’s FDA approval ...
Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...
A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025. Claims of ...
The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...
GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...
The CDMO will be cutting 350 jobs at its Baltimore gene therapy site after a major client’s demand shift, less than a year ...
The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.
New pill orforglipron was associated with a significant reduction in body weight and better cholesterol, triglycerides and blood pressure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results